What are the latest advances in Hodgkin's lymphoma?

Recent advances in Hodgkin’s lymphoma focus on reducing treatment toxicity while improving outcomes through precision medicine, specifically utilizing antibody-drug conjugates and immune checkpoint inhibitors. These therapies have significantly improved survival rates for patients with relapsed or refractory Hodgkin’s lymphoma, marking a shift toward more targeted, less chemotherapy-intensive treatment regimens.

What are the most promising research directions for Hodgkin's lymphoma?

Research into Hodgkin's lymphoma is currently prioritizing the reduction of long-term side effects from traditional chemotherapy and radiation. The most significant breakthroughs involve immunotherapy, particularly the use of PD-1 inhibitors like nivolumab and pembrolizumab, which have become staples in treating relapsed cases. Additionally, researchers are investigating "response-adapted" therapy, where PET scans are used mid-treatment to tailor the intensity of subsequent chemotherapy, sparing patients from unnecessary exposure to toxic drugs.

How are biologics and precision medicine changing Hodgkin's lymphoma treatment?

Precision medicine has revolutionized the landscape for patients with Hodgkin's lymphoma by introducing highly targeted biologics. Key advancements include:

• Brentuximab vedotin: An antibody-drug conjugate that specifically targets CD30-positive cells, a hallmark of Hodgkin's lymphoma.


• Checkpoint Inhibitors: Drugs that "release the brakes" on the immune system, allowing T-cells to identify and destroy lymphoma cells more effectively.


• CAR T-cell Therapy: Early-stage clinical trials are exploring the efficacy of chimeric antigen receptor (CAR) T-cell therapy for patients who have exhausted standard options.

How can patients find and participate in clinical trials?

Participation in clinical trials is vital for the development of new Hodgkin's lymphoma therapies. Patients should discuss trial eligibility with their hematologist-oncologist. To find active studies, patients can use ClinicalTrials.gov to filter by disease stage, previous treatments, and geographic location. The 116 members of the DiseaseMaps.org Hodgkin's lymphoma community often share personal experiences regarding trial participation, which can provide invaluable peer support during the decision-making process.

Next steps

• Consult your hematologist-oncologist about whether your specific subtype of Hodgkin's lymphoma qualifies for targeted therapy trials.


• Visit ClinicalTrials.gov and search using terms like "Relapsed Hodgkin's Lymphoma" to view active, recruiting studies.


• Join the DiseaseMaps.org community to connect with others who have navigated recent treatment advancements.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice; always consult a qualified healthcare professional regarding diagnosis and treatment.

References

• NIH National Cancer Institute (NCI) – Hodgkin Lymphoma Treatment Overview


• Orphanet – Hodgkin Lymphoma Rare Disease Database


• Leukemia & Lymphoma Society (LLS) – Latest Research and Clinical Trials


• PubMed – Recent Peer-Reviewed Literature on PD-1 Inhibitors in Lymphoma